About US
Contact us
-
Merck to build biologics research facility in New Jersey where plant will closeNews comes after its reported huge earnings decline this week Merck ($MRK) says it will shutter another plant as it continues to suffer from the patent loss of blockbusterSingulair, but it intends to2013/8/2
-
Sanofi CEO can't sugar-coat 'shocking' Q2 resultsBrazilian snafu, generic competition prompt cut to earnings forecastCall it what you will: chutzpah, optimism, wishful thinking, spin-doctoring, or just plain confidence. In any case, the headline on2013/8/2
-
US scientists make chemotherapy tolerance breakthrough in miceScientists in Michigan have discovered a biological mechanism that can preserve the gastrointestinal tracts of mice after a lethal dose of chemotherapy, a discovery that could lead to better tolerance2013/8/1
-
Pfizer to pay $491m over illegal marketing probePfizer has agreed to pay $491m (£320m) to settle an investigation into illegal marketing of the drug Rapamune by Wyeth, a company it acquired in 2009. Sales staff at Wyeth allegedly encouraged2013/8/1
-
Europe probing Germany's practice of cutting break on fees to some drugmakersFor more than a year, Big Pharma players have been adamantly complaining about the tight-fisted approachGermanytakes toward approving new drugs. Its pricing agency has rejected offerings right and lef2013/7/29
-
CFDA Vice Minister Yin Li meets Minister for Jobs, Enterprise and Innovation of Ireland and Ambassador of Ireland to ChinaOn the morning of July 24, 2013, Yin Li, Vice Minister of China Food and Drug Administration (CFDA) met with the delegation led by Mr. Richard Bruton, Minister for Jobs, Enterprise and Innovation of I2013/7/29
-
2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 3rd station--Guangzhou was successfully concluded2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 3rd station--Guangzhou was successfully concluded 2013 PhexTour （Pharma Excipients Technical Application National Tour2013/7/26
-
J&J getting ugly OTC episode behind itFort Washington plant nearly ready for FDA reinspection; J&J settles shareholder suit tied to its failings Sometime in the future, Johnson & Johnson ($JNJ) expects it will not have to talk ab2013/7/19
-
As bribery probe intensifies, China confines GlaxoSmithKline finance chief to its bordersGlaxoSmithKline's ($GSK) finance chief inChinais stuck. The government won't let him cross the border. In the midst of investigating the company for bribery, officials confined Steve Nechelput to the2013/7/19
-
Novartis raises guidance thanks to no-show Diovan genericWhy exactly a generic version of Novartis' blood-pressure drugDiovanhas yet to hit the market is a bit of a mystery, but one thing is clear: The company is benefiting from the delay. Novartis ($NVS),2013/7/18